Envista Stock (NYSE:NVST)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$24.61

52W Range

$14.22 - $30.42

50D Avg

$25.98

200D Avg

$21.70

Market Cap

$4.11B

Avg Vol (3M)

$2.89M

Beta

0.95

Div Yield

-

NVST Company Profile


Envista Holdings Corp. manufactures and markets dental products for diagnosing, treating and preventing dental conditions. The company is headquartered in Brea, California and currently employs 12,800 full-time employees. The firm provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone. The firm operates through two segments: Specialty Products & Technologies, and Equipment & Consumables. Its Specialty Products & Technologies segment develops, manufactures and markets dental implant systems, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners and lab products. Its Equipment & Consumables segment develops, manufactures and markets dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems; treatment units and other dental practice equipment; endodontic systems and related consumables; restorative materials and instruments, rotary burs, impression materials, bonding agents and cements and infection prevention products.

Show More

Industry

Medical - Equipment & Services

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

US

Employees

12,300

IPO Date

Sep 18, 2019

Website

NVST Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 24Dec 23Dec 22
Equipment and Consumables$894.20M$924.10M-
Specialty Products and Technologies$1.62B$1.64B-
Consumables--$2.15B
Equipment Sales--$421.60M

Fiscal year ends in Dec 25 | Currency in USD

NVST Financial Summary


Dec 25Dec 24Dec 23
Revenue$2.72B$2.51B$2.57B
Operating Income$225.70M$-1.04B$31.50M
Net Income$47.00M$-1.12B$-100.20M
EBITDA$341.70M$279.50M$463.00M
Basic EPS$0.28$-6.50$-0.60
Diluted EPS$0.28$-6.50$-0.60

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q4 25Feb 06, 26 | 5:00 PM
Q3 25Oct 31, 25 | 5:00 PM
Q2 25Jul 31, 25 | 5:00 PM

Peer Comparison


TickerCompany
GRALGRAIL, Inc.
ICUIICU Medical, Inc.
SUPNSupernus Pharmaceuticals, Inc.
RAREUltragenyx Pharmaceutical Inc.
PRVAPrivia Health Group, Inc.
ALHCAlignment Healthcare, Inc.
XRAYDENTSPLY SIRONA Inc.
DYNDyne Therapeutics, Inc.
CONConcentra Group Holdings Parent, Inc.
APGEApogee Therapeutics, Inc.